120 related articles for article (PubMed ID: 849604)
21. Inhibition of lymphocyte cytotoxicity for human colon carcinoma by treatment with solubilized tumour membrane fractions.
Baldwin RW; Embleton MJ; Price MR
Int J Cancer; 1973 Jul; 12(1):84-92. PubMed ID: 4790711
[No Abstract] [Full Text] [Related]
22. Cytotoxicity responses to melanoma cells by human lymphoid cell subpopulations.
O'Neill PA; Mackler BF; Romsdahl MM
J Natl Cancer Inst; 1976 Aug; 57(2):431-4. PubMed ID: 1087348
[TBL] [Abstract][Full Text] [Related]
23. Cellular immunity to a common human sarcoma antigen and its specific inhibition by sera from patients with growing sarcomas.
Cohen AM; Ketcham AS; Morton DL
Surgery; 1972 Oct; 72(4):560-7. PubMed ID: 4506654
[No Abstract] [Full Text] [Related]
24. Mediation of cytotoxic immune responses against human tumor-associated antigens by allogeneic immune RNA.
Kern DH; Fritze D; Schick PM; Chow N; Pilch YH
J Natl Cancer Inst; 1976 Jul; 57(1):105-9. PubMed ID: 1003493
[TBL] [Abstract][Full Text] [Related]
25. Cellular reactions against Burkitt lymphoma cells. 3. Effector cell activity of leukocytes stimulated in vitro with autochthonous cultured lymphoma cells.
Golub SH; Svedmyr EA; Hewetson JF; Klein G; Singh S
Int J Cancer; 1972 Jul; 10(1):157-64. PubMed ID: 4122454
[No Abstract] [Full Text] [Related]
26. Further definition by cytotoxicity tests of cell surface antigens of human sarcomas in culture.
Bloom ET
Cancer Res; 1972 May; 32(5):960-7. PubMed ID: 4502173
[No Abstract] [Full Text] [Related]
27. Use of an in vitro microcytotoxicity test to assess human tumor-specific cell-mediated immunity and its serum-mediated abrogation.
Levy NL
Natl Cancer Inst Monogr; 1973 Jun; 37():85-92. PubMed ID: 4576707
[No Abstract] [Full Text] [Related]
28. Cytotoxic antibodies to cultured melanoma cells in the sera of melanoma patients.
Ferrone S; Pellegrino MA
J Natl Cancer Inst; 1977 May; 58(5):1201-4. PubMed ID: 67208
[TBL] [Abstract][Full Text] [Related]
29. In vitro evidence of specific BCG-induced immunity to malignant melanoma in BALB-c mice.
Faraci RP; Barone JJ; Marrone JC; Schour L
J Natl Cancer Inst; 1974 Jun; 52(6):1913-5. PubMed ID: 4834418
[No Abstract] [Full Text] [Related]
30. Immunological studies of women with primary breast carcinoma.
Jeejeebhoy HF
Int J Cancer; 1975 Jun; 15(6):867-78. PubMed ID: 1150343
[TBL] [Abstract][Full Text] [Related]
31. Cellular immunity to human tumor-associated antigens. A review.
Herberman RB
Isr J Med Sci; 1973 Mar; 9(3):300-7. PubMed ID: 4575654
[No Abstract] [Full Text] [Related]
32. The use of viable frozen lymphocytes for studies in human tumor immunology.
Golub SH; Sulit HL; Morton DL
Transplantation; 1975 Mar; 19(3):195-202. PubMed ID: 124484
[TBL] [Abstract][Full Text] [Related]
33. Sensitization of T lymphocytes in vitro by syngeneic macrophages fed with tumor antigens.
Treves AJ; Schechter B; Cohen IR; Feldman M
J Immunol; 1976 Apr; 116(4):1059-64. PubMed ID: 1082902
[TBL] [Abstract][Full Text] [Related]
34. Specific cytotoxic lymphocytes against syngeneic tumors are generated in culture in the presence of syngeneic, but not xenogeneic, serum.
Fogel M; Segal S; Gorelik E; Feldman M
Int J Cancer; 1978 Sep; 22(3):329-34. PubMed ID: 81185
[TBL] [Abstract][Full Text] [Related]
35. In vitro lymphocyte immunization to cultured human tumor cells: parameters for generation of cytotoxic lymphocytes.
Sharma BS
J Natl Cancer Inst; 1976 Oct; 57(4):743-8. PubMed ID: 1003525
[TBL] [Abstract][Full Text] [Related]
36. Nonspecific lymphocyte cytotoxicity in patients with malignant melanoma, renal cell carcinoma, and sarcomas, and in nontumor patients.
Bukowski RM; Barna B; Deodhar SD; Hewlett JS
Cancer; 1976 Nov; 38(5):1962-7. PubMed ID: 991109
[TBL] [Abstract][Full Text] [Related]
37. In vitro cell-mediated immune reactions of melanoma and colorectal carcinoma patients demonstrated by long-term 51chromium assays.
Steele G; Sjögren HO; Stadenberg I
Int J Cancer; 1976 Jan; 17(1):27-39. PubMed ID: 1248900
[TBL] [Abstract][Full Text] [Related]
38. Specificity of in vitro cellular cytotoxicity against transitional cell carcinoma cell line T-24.
Catalona WJ; Oldham RK; Djeu JY; Herberman RB; Cannon GB
Surg Forum; 1975; 26():122-4. PubMed ID: 56048
[No Abstract] [Full Text] [Related]
39. Human malignant melanoma cells: morphological and immunological variations.
Hakim AA
Neoplasma; 1977; 24(1):81-99. PubMed ID: 840339
[TBL] [Abstract][Full Text] [Related]
40. In vitro sensitization to embryonic antigens.
Friend K; Hellström I; Hellström KE
Int J Cancer; 1976 Dec; 18(6):843-51. PubMed ID: 992911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
